...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: (one) case study
Reply New Message
Back To Forum List View
(one) case study
2
noretreat
Sep 04, 2018 06:16PM

Fair criticism no retreat. I enjoyed reading the detailed changes in ZEN-3694 dosing and PSA responses in the full manuscript. Great proof of principle but definitely more patients needed. Imagine if this CURATE.AI is applied to all Phase 2 patients!

BearDownAZ 

3 Recommendations
Icon president Re: (one) case study
8
SanFrancisco99
Sep 04, 2018 08:53PM
Re: (one) case study
5
Toinv
Oct 03, 2018 06:39PM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply